India Markets closed

Dr Reddy Settles Patent Litigation Suit; big boost for pharma sector

Pharma stocks clearly owe the market as of now and the recent rising trend has brought all the attention towards the pharma stocks, but most importantly on DRL. DRL has settled the patent litigation suit of US Revlimid Capsules and has been the outperforming stock since quite some time now, and is likely to maintain its position as an outperforming stock in the near future.

According to JP Morgan, gRevlimid settlement is positive and it could improve US visibility but could be competitive as well. Furthermore, Dr Reddy has seen an improved outlook in the US business. The launch of gVascepa in the near-term will be a key catalyst, states JP Morgan’s report.